Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells

The role of cyclooxygenase-2 (COX-2) in cancer remains controversial. Using cervical carcinoma cells (HeLa), the present study investigates the involvement of COX-2 in apoptosis elicited by the chemotherapeutics paclitaxel, cisplatin and 5-fluorouracil. Each compound led to a profound induction of COX-2 expression and prostaglandin (PG) synthesis, accompanied by a substantial decrease of viability and enhanced apoptosis. Cells were significantly less sensitive to apoptotic death when either COX-2 expression or its activity was suppressed by small-interfering RNA (siRNA) and by the selective COX-2 inhibitor NS-398, respectively. Experiments performed to clarify how COX-2 leads to apoptosis revealed a profound proapoptotic action of PGD2 and its dehydration product, 15-deoxy-Δ12,14 PGJ2 (15d-PGJ2). In line with these findings, chemotherapeutics-induced apoptosis was prevented by siRNA targeting lipocalin-type PGD synthase (L-PGDS), which catalyses the isomerization of PGH2 to PGD2. Moreover, apoptosis by chemotherapeutics, PGD2 and 15d-PGJ2 was suppressed by the peroxisome proliferator-activated receptor γ (PPARγ) antagonist, GW-9662 or PPARγ siRNA. Finally, a COX-2-dependent apoptotic mechanism of all investigated chemotherapeutics was confirmed in human lung cancer cells (A549) as well as in another cervical carcinoma cell line (C33A). Collectively, this study suggests COX-2 induction and synthesis of L-PGDS-derived, PPARγ-activating PGs as a decisive target by which several chemotherapeutics induce apoptosis. COX-2 is therefore suspected to sensitize cancer cells to apoptotic death under certain circumstances, suggesting that COX-2 inhibition during cancer therapy could diminish its efficacy.

[1]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[2]  A. Ristimäki,et al.  Tumorigenic Transformation of Immortalized ECV Endothelial Cells by Cyclooxygenase-1 Overexpression* , 1997, The Journal of Biological Chemistry.

[3]  M. Willingham,et al.  Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. , 1999, Carcinogenesis.

[4]  R. Langenbach,et al.  Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (Nsaids) on Cyclooxygenase-Null Embryo Fibroblasts , 1999, The Journal of experimental medicine.

[5]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[6]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[7]  Federico Innocenti,et al.  Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. , 2002, British journal of clinical pharmacology.

[8]  A. Finazzi-Agro’,et al.  Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. , 2002, The Biochemical journal.

[9]  A. Dannenberg,et al.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. , 2002, Neoplasia.

[10]  R. Ramer,et al.  Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. , 2003, Molecular pharmacology.

[11]  P. van Bladeren,et al.  The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. , 2003, Carcinogenesis.

[12]  D. Yankelevitz,et al.  Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Fürstenberg,et al.  Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference , 2003, Oncogene.

[14]  Y. Surh,et al.  Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. , 2003, Biochemical pharmacology.

[15]  M. Gandelman.  Celecoxib: a selective cyclooxygenase-2 inhibitor , 2003, Arthritis Research & Therapy.

[16]  R. Ramer,et al.  Up-Regulation of Cyclooxygenase-2 Expression Is Involved in R(+)-Methanandamide-Induced Apoptotic Death of Human Neuroglioma Cells , 2004, Molecular Pharmacology.

[17]  Hualiang Jiang,et al.  A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist. , 2004, Analytical biochemistry.

[18]  T. Dang,et al.  Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel , 2005, Clinical Cancer Research.

[19]  A. Gajra,et al.  Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. , 2005, Lung cancer.

[20]  S. Shen,et al.  Prostaglandin D2 and J2 induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species , 2005 .

[21]  Robert A Newman,et al.  Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. , 2005, Cancer research.

[22]  R. Ramer,et al.  R(+)-Methanandamide Elicits a Cyclooxygenase-2-Dependent Mitochondrial Apoptosis Signaling Pathway in Human Neuroglioma Cells , 2006, Pharmaceutical Research.

[23]  A. Argiris,et al.  Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer , 2006, Investigational New Drugs.

[24]  H. Inoue,et al.  Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. , 2005, Biochemical and biophysical research communications.

[25]  Y. Surh,et al.  ET‐18‐O‐CH3‐induced apoptosis is causally linked to COX‐2 upregulation in H‐ras transformed human breast epithelial cells , 2005, FEBS letters.

[26]  Liang Cheng,et al.  A Phase II Trial of Irinotecan, 5-Fluorouracil and Leucovorin Combined with Celecoxib and Glutamine as First-Line Therapy for Advanced Colorectal Cancer , 2005, Oncology.

[27]  M. Hansen,et al.  Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. , 2006, Cancer research.

[28]  S. Martin,et al.  Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients’ survival in glioblastoma multiforme , 2007, Oncogene.